Pramipexole as adjunct to haloperidol in schizophrenia

Kasper, Siegfried; Barnas, C.; Heiden, A.; Volz, Hans-Peter; Laakmann, G.; H, Zeit; Pfolz, H

doi:10.1016/s0924-977x(96)00393-8

Cited by 35 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, in both cases, the articles discuss (potential) adverse events of drugs, which is reflected in the indexing. For example, an article whose conclusion is “This study supports the safety of the treatment of schizophrenia with pramipexole and haloperidol as a combination therapy” [32] is appropriately indexed with Pramipexole and Dyskinesia, Drug-Induced despite the fact that the authors demonstrate the lack of worsening of extrapyramidal side effects.…”

Section: Methods and Resultsmentioning

confidence: 99%

Leveraging MEDLINE indexing for pharmacovigilance – Inherent limitations and mitigation strategies

Winnenburg¹,

Sorbello

Ripple³

et al. 2015

Journal of Biomedical Informatics

View full text Add to dashboard Cite

Background Traditional approaches to pharmacovigilance center on the signal detection from spontaneous reports, e.g., the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS). In order to enrich the scientific evidence and enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes, pharmacovigilance activities need to evolve to encompass novel complementary data streams, for example the biomedical literature available through MEDLINE. Objectives 1) to review how the characteristics of MEDLINE indexing influence the identification of adverse drug events (ADEs); 2) to leverage this knowledge to inform the design of a system for extracting ADEs from MEDLINE indexing; and 3) to assess the specific contribution of some characteristics of MEDLINE indexing to the performance of this system. Methods We analyze the characteristics of MEDLINE indexing. We integrate three specific characteristics into the design of a system for extracting ADEs from MEDLINE indexing. We experimentally assess the specific contribution of these characteristics over a baseline system based on co-occurrence between drug descriptors qualified by adverse effects and disease descriptors qualified by chemically induced. Results Our system extracted 405,300 ADEs from 366,120 MEDLINE articles. The baseline system accounts for 297,093 ADEs (73%). 85,318 ADEs (21%) can be extracted only after integrating specific pre-coordinated MeSH descriptors and additional qualifiers. 22,889 ADEs (6%) can be extracted only after considering indirect links between the drug of interest and the descriptor that bears the ADE context. Conclusions In this paper, we demonstrate significant improvement over a baseline approach to identifying ADEs from MEDLINE indexing, which mitigates some of the inherent limitations of MEDLINE indexing for pharmacovigilance. ADEs extracted from MEDLINE indexing are complementary to, not a replacement for, other sources.

show abstract

Section: Methods and Resultsmentioning

confidence: 99%

Leveraging MEDLINE indexing for pharmacovigilance – Inherent limitations and mitigation strategies

Winnenburg¹,

Sorbello

Ripple³

et al. 2015

Journal of Biomedical Informatics

View full text Add to dashboard Cite

show abstract

“…These various ways of defining quality of life range from vague definitions of “whatever the individual defines it to be,” “ability to lead a normal life” and “self-actualization,” to more thoughtful and considered definitions such as those that emphasize fulfillment of personal goals 53. In any case, data on the impact of aripiprazole therapy on the quality of life of schizophrenic patients are scarce and characterized by conflicting results 39,40,56,58. In addiction, until now studies lasting more than 26 weeks are unavailable.…”

Section: Discussionmentioning

confidence: 99%

“…In fact, despite the peculiar activity of aripiprazole at D 2 receptors (associated with both reduced neurocognitive effects and an improved neurological tolerability) 56,57,58. it has been conversely suggested that there are no beneficial effects of aripiprazole on general cognitive and executive functioning 19.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

Gentile¹

2009

NDT

View full text Add to dashboard Cite

Aripiprazole is a relatively novel second-generation antipsychotic belonging to the chemical class of benzisoxazole derivatives and is characterized by a unique pharmacological profile which suggests that the drug acts as a dopamine-serotonin system stabilizer. Whereas all previously available antipsychotics are antagonists at D2 receptors, aripiprazole is the only available partial agonist at these receptors. Thus, it has been suggested that aripiprazole could be associated with a relatively neutral impact on bodyweight, possibly reducing risks of a detrimental impact on the quality of life that often complicates management for a large number of patients diagnosed with severe and persistent mental disorders (SPMDs) treated chronically with antipsychotic medications. However, data from short- and long-term reviewed studies indicate that the prevalence rate of clinically relevant weight gain during therapy with this drug is similar to that occurring during treatments with other antipsychotic agents, either typical or atypical. Moreover, information on the impact of aripiprazole therapy on the quality of life of patients diagnosed with SPMDs is scarce and characterized by conflicting results. Given these results, further, large, well-designed studies are needed before confirming potential advantages of aripiprazole over first-generation antipsychotics and other SGAs.

show abstract

“…Haasio 2010)] carry other medical contraindications. However, DA agonists have been used safely in schizophrenia for many years (e.g., Benkert et al 1995; Kasper et al 1997), and—as suggested by Barch (2010) and others—their use in concert with antipsychotics might prevent potentially deleterious effects of subcortical D 2 activation, while permitting potentially beneficial activation of cortical D 1 receptors. Whether there is a role for some of these agents in biomarker-identified subpopulations, in time-limited combinations with CT and antipsychotic agents, remains an empirical question.…”

Section: Examples Of Candidate “Pro-ct” Drugsmentioning

confidence: 99%

Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia

Chou

Twamley

Swerdlow

2012

Novel Antischizophrenia Treatments

View full text Add to dashboard Cite

Current antipsychotic medications do little to improve real-life function in most schizophrenia patients. A dispassionate view of the dispersed and variable neuropathology of schizophrenia strongly suggests that it is not currently, and may never be, correctable with drugs. In contrast, several forms of cognitive therapy have been demonstrated to have modest but lasting positive effects on cognition, symptoms, and functional outcomes in schizophrenia patients. To date, attempts to improve clinical outcomes in schizophrenia by adding pro-cognitive drugs to antipsychotic regimens have had limited success, but we propose that a more promising strategy would be to pair drugs that enhance specific neurocognitive functions with cognitive therapies that challenge and reinforce those functions. By using medications that engage spared neural resources in the service of cognitive interventions, it might be possible to significantly enhance the efficacy of cognitive therapies. We review and suggest several laboratory measures that might detect potential pro-neurocognitive effects of drugs in individual patients, using a “test dose” design, aided by specific biomarkers predicting an individual’s drug sensitivity. Lastly, we argue that drug classes viewed as “counter-intuitive” based on existing models for the pathophysiology of schizophrenia—including pro-catecholaminergic and NMDA-antagonistic drugs—might be important candidate “pro-cognitive therapy” drugs.

show abstract

Pramipexole as adjunct to haloperidol in schizophrenia

Cited by 35 publications

References 17 publications

Leveraging MEDLINE indexing for pharmacovigilance – Inherent limitations and mitigation strategies

Leveraging MEDLINE indexing for pharmacovigilance – Inherent limitations and mitigation strategies

A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia

Contact Info

Product

Resources

About